Skip to content

Effective Phaco Time and Endothelial Cell Loss When Using Veritas

Assessment of Effective Phaco Time and Endothelial Cell Loss When Using a Novel Dual Mode Phacoemulsification System

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07176416
Enrollment
50
Registered
2025-09-16
Start date
2025-10-03
Completion date
2026-10-01
Last updated
2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.

Interventions

Veritas Vision System

Sponsors

Sengi
CollaboratorINDUSTRY
Aloha Vision Consultants
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Adult patients undergoing age-related cataract surgery. * Planned use of the Catalys Precision Laser System. * Planned implantation of TECNIS intraocular lenses (IOLs).

Exclusion criteria

• Moderate-severe any disease state (deemed by the surgeon) that could increase risk of complicated cataract surgery (ie, pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma, and prior refractive surgery).

Design outcomes

Primary

MeasureTime frame
Effective phaco time per phacoemulsification procedureSurgery (Day 0)

Secondary

MeasureTime frameDescription
Endothelial cell loss1 monthspostoperatively
Total case timeSurgery (Day 0)total case time per procedure
Total phaco timeSurgery (Day 0)total phaco time per procedure
Total volume usedSurgery (Day 0)Total volume used per procedure

Countries

United States

Contacts

Primary ContactAlana K Dunn
avc.alanad@gmail.com808-688-6898

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026